The outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) infections poses a threat to public health worldwide. Although the predicted pandemic potential of MERS remains low, an increase in the sustainability of human-to-human transmission, as a result of further evolution of MERS-CoV in nature, is of concern. To date, neither the pathogenesis nor effective intervention against this newly emerged human disease is available, largely due to the lack of animal species, especially, the small laboratory species that can recapitulate clinical illness in response to infection. Understanding the mechanism used by MERS-CoV to cause diseases in suitable animal models can help in identifying novel targets for the development of effective therapeutics. While nonhuman primates (NHP) (i.e., rhesus macaques) are permissive to MERS-CoV, the infection in NHPs results in the onset of acute, but self-resolving, respiratory stress without any mortality. Moreover, the high cost, varying degrees of histopathology, and the nature of transient and limited clinical illness make this model less attractive, especially for testing vaccines and therapeutics. Development of animal models has recently been listed as a prioritized area of MERS-CoV research by NIH/NIAID. Our laboratory has previously reported that mice which are inheritably resistant to clinical illness associated with SARS-CoV infection became fully permissive to the virus, resulting in morbidity and mortality, when expressing human ACE2 viral receptor. Based on our prior success, we propose establishing transgenic mice expressing the human CD26/DPPIV (hCD26) viral receptor as the small animal model for MERS-CoV. As the expression of hCD26 is not restricted to the lungs, we will generate transgenic mouse lineages with either constitutive (Aim 1) or lung-specific expression of hCD26 (Aim 2) in this application, as an alternative to the existing NHP model. Successful establishment of these transgenic mouse models will be useful not only for studying morbidity, mortality, and viral replication in humans, but also for evaluating preventive and therapeutic agents developed against MERS-CoV.
Middle East respiratory syndrome (MERS), caused by a novel coronavirus (CoV), is a highly contagious, life-threatening human respiratory pathogen, with a case-fatality rate of 43%. To date, neither the pathogenesis nor effective intervention against this newly emerged human disease is available, largely due to the lack of suitable animal species. In this application, we propose establishing transgenic mice expressing human CD26 viral receptor, as small animal models, to study MERS-CoV pathogenesis and evaluate the protective efficacy of experimental vaccines and drugs against MERS.
|Agrawal, Anurodh Shankar; Tao, Xinrong; Algaissi, Abdullah et al. (2016) Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 12:2351-6|
|Agrawal, Anurodh Shankar; Ying, Tianlei; Tao, Xinrong et al. (2016) Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Sci Rep 6:31629|
|Du, Lanying; Tai, Wanbo; Yang, Yang et al. (2016) Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun 7:13473|
|Tao, Xinrong; Garron, Tania; Agrawal, Anurodh Shankar et al. (2016) Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Virol 90:57-67|
|Agrawal, Anurodh Shankar; Garron, Tania; Tao, Xinrong et al. (2015) Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 89:3659-70|